Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy
Lists
Only you see this
Abstract
Similar to AD, the interpretation of [<sup>18</sup>F]THK5351 uptake in PSP is likely confounded by off-target binding to MAO-B binding sites. [<sup>18</sup>F]THK5351 is not sufficient in quantifying tau aggregates in PSP using the proposed rasagiline dosing regimen.
BibTeX
@inproceedings{ng2019rasagiline,
author = {Kok Pin Ng and Joseph Therriault and Min Su Kang and Hanne Struyfs and Tharick A. Pascoal and Sulantha Mathotaarachchi and Monica Shin and Andréa Lessa Benedet and Gassan Massarweh and Jean‐Paul Soucy and Pedro Rosa‐Neto and Serge Gauthier},
title = {{Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [18F]THK5351 uptake in progressive supranuclear palsy}},
booktitle = {NeuroImage},
year = {2019},
doi = {10.1016/j.nicl.2019.102091},
}Loading related content...